VLA Valneva SE

By Stephen Nakrosis

The Food and Drug Administration said it granted approval of Ixchiq, the first vaccine for chikungunya virus, to Valneva Austria.

Valneva Austria's parent company is France's Valneva SE.

The FDA said Thursday chikungunya is a mosquito-borne disease, which causes symptoms including headache, fever, joint pain and rash. The virus is an emerging global health threat, with at least 5 million cases of infection reported over the past 15 years, according to the FDA.

Ixchiq was approved for those 18 years of age and older who are at increased risk of exposure to chikungunya virus, the FDA said.

Trade in Valneva's America depositary receipts was halted after hours Thursday because of pending news.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

November 09, 2023 18:20 ET (23:20 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.